ONCOLYTICS BIOTECH INC 8-K

What Happened
On July 6, 2026, Oncolytics Biotech Inc. announced via Form 8-K that its Audit Committee unanimously voted to disengage Ernst & Young LLP (EY) as the company’s independent registered public accounting firm and to engage Baker Tilly US, LLP as its new independent auditor for the 2026 fiscal year. The change was made in connection with the company’s corporate restructuring and is subject to Baker Tilly’s completion of client acceptance procedures. The company filed the Form 8-K on July 8, 2026.

Key Details

• The Audit Committee’s vote to change auditors occurred on July 6, 2026.
• EY’s audit reports for the fiscal years ended December 31, 2025 and December 31, 2024 were unqualified and did not contain adverse opinions or disclaimers; they did include an explanatory paragraph about the company’s ability to continue as a going concern.
• There were no disagreements or reportable events with EY during 2024–2025 or through the date of the change.
• Baker Tilly had not previously provided the company with consultation on accounting or auditing matters, and the engagement is subject to Baker Tilly’s client acceptance procedures.
• The company provided EY a copy of the Form 8-K and requested a letter from EY (Exhibit 16.1).

Why It Matters
A change in independent auditor is a governance event investors should note because it affects who reviews and signs off on the company’s financial statements. This filing indicates the change was driven by restructuring (not by auditor disagreements) and that prior EY audits were unmodified aside from a going-concern note. Investors should watch for future filings confirming Baker Tilly’s acceptance and for any subsequent audit opinions or disclosures that could affect financial statement reliability or the company’s reported ability to continue as a going concern.